Capricor Therapeutics (CAPR) is analyzed ahead of an FDA decision, with the current focus on its pre-commercial stage and future revenue potential.
Source Post
Capricor: 112% Upside Ahead of FDA Decision! | CAPR Stock Analysis
Jun 18, 2026
This podcast episode analyzes Capricor Therapeutics (CAPR), a clinical-stage biotech company focused on Duchenne muscular dystrophy. The discussion highlights the company's upcoming FDA decision date (August 22, 2026), its current financial state with zero revenue and widening losses, and the forward-looking thesis based on projected high revenue from a high-priced therapy for a rare disease. The analysis also touches on the challenges of healthcare system affordability for such treatments.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
No linked signals were opened directly from this post.